文献速递慢性肾脏病水电解质与酸碱肾血管病与高血压

高钾血症相关RAASi减量与后续住院增加相关

Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该研究基于瑞典和日本登记数据,纳入CKD和/或HF正在使用RAASi且发生高钾血症的患者,按事件后RAASi维持或减量分组并行倾向评分匹配。结果显示减量组全因住院日增加更多、存活且非住院天数更少,提示高钾血症相关RAASi减量与后续住院负担增加相关。

要点

  • 高钾血症后RAASi减量者全因住院日增加幅度高于维持者。
  • 瑞典和日本队列中减量组存活且非住院天数均少于维持组。
  • 高钾血症相关RAASi减量可能提示后续住院风险增加。

核心结论

  • 高钾血症事件后RAASi治疗减量的患者比维持治疗者住院日更多、存活且非住院天数更少。

研究设计与样本

  • 基于瑞典和日本健康登记与医院病历数据,纳入CKD和/或HF正在使用RAASi且发生高钾血症指数的患者。
  • 按事件后RAASi维持或减量分组,应用1:1倾向评分匹配平衡基线特征。

主要发现

  • 瑞典队列42%、日本队列38%的患者在高钾血症事件后减少RAASi治疗。
  • 事件后6个月,减量组全因住院每人年增加:瑞典18.2天(95%CI 17.0-19.2),日本17.9天(95%CI 17.4-18.5)。
  • 维持组全因住院每人年增加:瑞典9.4天(95%CI 8.6-10.4),日本8.5天(95%CI 8.0-9.0)。
  • 减量组平均DAOH:瑞典121.5(SD 75.0),日本141.7(SD 54.5);维持组分别为154.0(SD 51.3)和157.5(SD 31.6)。

临床怎么用

  • 对CKD和/或HF使用RAASi者发生高钾血症后,应评估减量决策并关注后续住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperkalaemia is a barrier to achieving optimal, guideline-directed treatment with renin-angiotensin-aldosterone system inhibitors (RAASis) in patients with chronic kidney disease (CKD) and/or heart failure (HF). This study describes the association between hyperkalaemia-related RAASi treatment reduction and the number of hospitalized days in patients with CKD and/or HF in Sweden and Japan. METHODS: Using data from health registers and hospital medical records, patients with CKD and/or HF currently receiving RAASis who experienced an index hyperkalaemia episode were identified and categorized as having maintained or reduced RAASi treatment post-index; propensity score matching (1:1) was applied to balance the groups in terms of baseline characteristics. Changes in the number of all-cause, CKD- and HF-related hospitalized days per patient-year during 6 months pre- versus post-index and the number of days alive and out of hospital (DAOH) during 6 months post-index were described. RESULTS: Overall, 20 824 and 7789 patients were included from Sweden and Japan, respectively, 42% and 38% of whom reduced their RAASi treatment after the index hyperkalaemia episode. During the 6 months post-index, all-cause hospitalization increased by 18.2 days [95% confidence interval (CI) 17.0-19.2] per person-year in Sweden and 17.9 days (95% CI 17.4-18.5) per person-year in Japan among patients with reduced RAASi treatment compared with increases of 9.4 days (95% CI 8.6-10.4) and 8.5 days (95% CI 8.0-9.0) per person-year, respectively, among patients with maintained RAASi treatment. The mean DAOH was 121.5 [standard deviation (SD) 75.0] in Sweden and 141.7 (SD 54.5) in Japan among patients with reduced RAASi treatment compared with 154.0 (SD 51.3) and 157.5 (SD 31.6), respectively, among patients with maintained RAASi treatment. CONCLUSION: Patients whose RAASi treatment was reduced after a hyperkalaemia episode had more hospitalized days and fewer DAOH compared with patients whose RAASi treatment was maintained.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Svensson MK, Murohara T, Lesén E, et al. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care. Nephrol Dial Transplant. 2024. PMID: 38253386. doi:10.1093/ndt/gfae016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。